CorMedix (CRMD) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurogene (NGNE) has outperformed CorMedix (CRMD) over the past year, gaining 2.6% versus a loss of 35.0%. Over five years, CRMD leads with a +47.9% price change compared with -81.6% for NGNE. CorMedix is the larger company by market cap ($578.0 million vs $540.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | NGNE |
|---|---|---|
| Share price | $7.42 | $27.01 |
| Market cap | $577.96M | $540.41M |
| 1-day change | +1.30% | +1.91% |
| YTD return | -37.06% | +28.64% |
| 1-year return | -35.05% | +2.59% |
| 5-year return | +47.88% | -81.65% |
| P/E ratio (TTM) | 3.62 | — |
| Forward P/E | 21.19 | — |
| EPS (TTM) | $2.05 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $43.66 |
| 52-week low | $6.13 | $15.93 |
| Distance from 52-week high | -43.05% | -38.15% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +106.74% | +188.39% |
| Average volume | 1.06M | 247.13K |
| Shares outstanding | 77.94M | 20.01M |
| Employees | 191 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed CRMD by 37.6 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
CRMD vs NGNE FAQ
Which is bigger, CorMedix or Neurogene?
CorMedix (CRMD) is larger, with a market capitalization of $577.96M compared with $540.41M for Neurogene (NGNE).
Which stock has performed better over the past year, CRMD or NGNE?
NGNE returned +2.59% over the past 12 months, compared with -35.05% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.